What is AZN's current stock price?

As of now, AZN is trading at $204.47, with a daily change of +5.77%.

What are the risks associated with AZN stock?

AZN has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN

Astrazeneca

$204.47

+$11.07 | +5.77%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$204.92

MKT CAP

$641.78B

52W Low

$122.26

VOL

$2.61M

P/E Ratio

N/A

AVG VOL

$7.24M

RSI

87.58

TREND

Uptrend

AZN Stock IQ

Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Target Price

Login to display

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Expands stock buyback program

AZN Price Performance

$93.99 (+117.54%)

$89.4 (+128.71%)

$76.28 (+168.05%)

$76.21 (+168.30%)

1year

6month

3month

1month

AZN Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

33%

100%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with events and the stock performance

82%

16%

Positive

Negative

41 out of 50
events present

8 out of 50
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$202.09

Resistance
Price

$106.65

Current Price Range

N/A

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

7

0

Date

Action

Rating

Firm

Feb 03, 2026

Upgrade

Hold

Jan 29, 2026

Initiate

Buy

Citigroup

Dec 06, 2025

Reiterate

Overweight

JP Morgan

Nov 12, 2025

Reiterate

Buy

Jefferies

Nov 12, 2025

Reiterate

Overweight

JP Morgan

AZN Latest Analysis +

AstraZeneca awards $3.4 million to United States nonprofits to expand healthcare access.

Today

$204.47 | +5.77%

Activity

AstraZeneca sets sights on 25 blockbusters by 2030 to fuel $80B revenue ambition. After ending 2025 with a strong fourth quarter AstraZeneca management has doubled down on its ambitious $80 billion by 2030 revenue target outlining a roadmap to have more than 25 blockbuster medicines by the end of the decade.During AZs Q4 earnings call CEO Pascal Soriot highlighted an

Today

$204.47 | +5.77%

Earnings

AstraZeneca PLC declares $2.17 dividend.

Tue Feb 10, 2026

$193.10 | +2.71%

Activity

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes Upgrading To Buy.

Tue Feb 10, 2026

$193.10 | +2.71%

Rating

AstraZeneca Reiterates $80 Billion 2030 View Ahead Of Catalyst-Rich 2026. AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.The post AstraZeneca Reiterates $80 Billion 2030 View Ahead Of '.Catalyst-Rich 2026'. appeared first on Investor'.s Business Daily.

Tue Feb 10, 2026

$193.10 | +2.71%

Earnings

AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth. ) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion up 4% year over year (2% at constant currency or cc) almost in line with .The adjusted earnings were $2.12 per share beating the consensus of $2.09.AstraZeneca’.s cancer business accounted for 45% of total sales. It 11% (9% cc) to $7.03 billion.Tagrisso sales were up 12% to $1.90 billion (10% cc) Imfinzi revenues were up 39% (37% cc) to $1.75 bill

Tue Feb 10, 2026

$193.10 | +2.71%

Potential

Earnings Snapshot: AstraZeneca beats Q4 revenue estimates. initiates FY outlook.

Tue Feb 10, 2026

$193.10 | +2.71%

Earnings

AstraZeneca rises as cancer drugs power Q4 beat.

Tue Feb 10, 2026

$193.10 | +2.71%

Momentum

AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat. AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.The post AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat appeared first on Investor'.s Business Daily.

Tue Feb 10, 2026

$193.10 | +2.71%

Earnings

Jim Cramer on Coca-Colas Retiring CEO: He Will Be missed. The Coca-Cola Company (NYSE:KO) is one of the stocks in focus on Jim Cramers game plan. Cramer noted the CEOs retirement as he commented:On Tuesday were back in heavy earnings rotation. Weve got DuPont Coca-Cola CVS Health AstraZeneca Datadog and S&.P Global report PepsiCo stock went

Tue Feb 10, 2026

$193.10 | +2.71%

Activity

Runners Also Watch

Close Price

Change

PFE

Pfizer

27.81

+0.72%

MRK

Merck Company

119.20

+1.79%

NVS

Novartis AG

159.93

+1.09%

HCM

HUTCHMED (China) Limited

15.12

+1.07%

TEVA

Teva Pharma

34.37

-0.01%

FAQ About AZN Stock Insights

What is AZN current stock price?

What are AZN stock strengths?

What is AZN Risk Level?

What is AZN market cap and volume?

What is AZN current Stock IQ?

Should I buy AZN stock right now?

Is AZN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AZN?

What does a 'Strong Sell' rating mean for AZN?

What factors influence AZN's Stock IQ?

Explore our AZN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AZN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AZN Daily Alerts

Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AZN

Astrazeneca

Set Alerts

Current Price

$204.47

+$11.07 | +5.77%

52W High

$204.92

MKT CAP

$641.78B

52W Low

$122.26

VOL

$2.61M

P/E Ratio

N/A

AVG VOL

$7.24M

RSI

87.58

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

PFE

Pfizer

27.81

+0.72%

MRK

Merck Company

119.20

+1.79%

NVS

Novartis AG

159.93

+1.09%

HCM

HUTCHMED (China) Limited

15.12

+1.07%

TEVA

Teva Pharma

34.37

-0.01%

AZN Price Performance

$93.99 (+117.54%)

$89.4 (+128.71%)

$76.28 (+168.05%)

$76.21 (+168.30%)

1year

6month

3month

1month

AZN Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

33%

100%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with events and the stock performance.

82%

16%

Positive

Negative

41 out of 50
events present

8 out of 50
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$202.09

Resistance
Price

$106.65

Current Price Range

N/A

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

7

0

Date

Action

Rating

Firm

Feb 03, 2026

Upgrade

Hold

Jan 29, 2026

Initiate

Buy

Citigroup

Dec 06, 2025

Reiterate

Overweight

JP Morgan

Nov 12, 2025

Reiterate

Buy

Jefferies

Nov 12, 2025

Reiterate

Overweight

JP Morgan

AZN Stock IQ

Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Expands stock buyback program

AZN Latest Analysis

AstraZeneca awards $3.4 million to United States nonprofits to expand healthcare access.

Today

$204.47 | +5.77%

Activity

AstraZeneca sets sights on 25 blockbusters by 2030 to fuel $80B revenue ambition. After ending 2025 with a strong fourth quarter AstraZeneca management has doubled down on its ambitious $80 billion by 2030 revenue target outlining a roadmap to have more than 25 blockbuster medicines by the end of the decade.During AZs Q4 earnings call CEO Pascal Soriot highlighted an

Today

$204.47 | +5.77%

Earnings

AstraZeneca PLC declares $2.17 dividend.

Tue Feb 10, 2026

$193.10 | +2.71%

Activity

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes Upgrading To Buy.

Tue Feb 10, 2026

$193.10 | +2.71%

Rating

AstraZeneca Reiterates $80 Billion 2030 View Ahead Of Catalyst-Rich 2026. AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.The post AstraZeneca Reiterates $80 Billion 2030 View Ahead Of '.Catalyst-Rich 2026'. appeared first on Investor'.s Business Daily.

Tue Feb 10, 2026

$193.10 | +2.71%

Earnings

AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth. ) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion up 4% year over year (2% at constant currency or cc) almost in line with .The adjusted earnings were $2.12 per share beating the consensus of $2.09.AstraZeneca’.s cancer business accounted for 45% of total sales. It 11% (9% cc) to $7.03 billion.Tagrisso sales were up 12% to $1.90 billion (10% cc) Imfinzi revenues were up 39% (37% cc) to $1.75 bill

Tue Feb 10, 2026

$193.10 | +2.71%

Potential

Earnings Snapshot: AstraZeneca beats Q4 revenue estimates. initiates FY outlook.

Tue Feb 10, 2026

$193.10 | +2.71%

Earnings

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AZN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AZN Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AZN Stock trends

AZN Stock performance

AZN Stock analysis

AZN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN Stock IQ

AZN Target Price

AZN Analysts Opinion

AZN Street Sentiment

AZN Risk Level

AZN Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our AZN Stock insights

Receive our AZN Daily Alerts

AZN Street Sentiment

AZN Risk Level

Key Price Levels

Latest Analyst Actions

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AZN. We're here to help you make informed investment decisions today.

Receive our AZN Daily Alerts

AZN Alerts